Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Scleroderma Therapeutics Market: By Drug Class: Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Others; By Indication; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Scleroderma Therapeutics Market Outlook
The global scleroderma therapeutics market attained a value of USD 1.7 billion in 2020. The scleroderma therapeutics market is further expected to grow in the forecast period of 2022-2027 at a CAGR of 6.2% to reach USD 2.4 billion by 2026.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Properties and Applications
Scleroderma refers to an autoimmune condition that affects the skin, vessels of the blood, muscles, and internal organs. Usually, the disease is caused by an abnormal immune response. Immunosuppressive medicines and, in some cases, glucocorticoids are included to treat this condition.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The drug class available in the industry can be divided into:
- Immunosuppressors
- Phosphodiesterase 5 Inhibitors - PHA
- Endothelin Receptor Antagonists
- Prostacyclin Analogues
- Calcium Channel Blockers
- Analgesics
- Others
Based on indication, the scleroderma therapeutics market can be divided into:
- Systemic
- Localized
The EMR report looks into the regional markets of scleroderma therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The demand in the industry is mainly being driven by the use of off-label medications approved. The lack of curative drugs and a higher prevalence of off-label drug use are the underlying factors that drive interest in markets for rare diseases. The advancement of targeted biologics, as well as small molecular combination therapies, are expected to be supported in the industry. The market is also projected to be supported by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment. The rising disposable incomes, allowing greater expenditure, and the existence of a well-defined regulatory framework that promotes successful therapy production in developed regions are driving the growth of the industry.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global scleroderma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- F. Hoffman La Roche Ltd.
- Boehringer Ingelheim International GmbH
- arGentis™ Pharmaceuticals, LLS
- Kadmon Holdings, Inc.
- Emerald Health Pharmaceuticals. Inc.
- Others
The EMR report gives an in-depth insight into the scleroderma therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2020 |
| Historical Period | 2017-2021 |
| Forecast Period | 2022-2027 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Drug Class, Indication, Region |
| Breakup by Drug Class | Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others |
| Breakup by Indication | Systemic, Localized |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, arGentis™ Pharmaceuticals, LLS, Kadmon Holdings, Inc., Emerald Health Pharmaceuticals Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Scleroderma Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Scleroderma Therapeutics Historical Market (2017-2021)
8.3 Global Scleroderma Therapeutics Market Forecast (2022-2027)
8.4 Global Scleroderma Therapeutics Market by Drug Class
8.4.1 Immunosuppressors
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Phosphodiesterase 5 Inhibitors - PHA
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Endothelin Receptor Antagonists
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Prostacyclin Analogues
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Calcium Channel Blockers
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2017-2021)
8.4.5.3 Forecast Trend (2022-2027)
8.4.6 Analgesics
8.4.6.1 Market Share
8.4.6.2 Historical Trend (2017-2021)
8.4.6.3 Forecast Trend (2022-2027)
8.4.7 Others
8.5 Global Scleroderma Therapeutics Market by Indication
8.5.1 Systemic
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Localised
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.6 Global Scleroderma Therapeutics Market by Region
8.6.1 Market Share
8.6.1.1 North America
8.6.1.2 Europe
8.6.1.3 Asia Pacific
8.6.1.4 Latin America
8.6.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 F. Hoffman-La Roche Ltd.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Boehringer Ingelheim International GmbH
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 arGentis™ Pharmaceuticals, LLS
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 Kadmon Holdings, Inc.
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Emerald Health Pharmaceuticals Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Scleroderma Therapeutics Market: Key Industry Highlights, 2017 and 2027
2. Global Scleroderma Therapeutics Historical Market: Breakup by Drug Class (USD Billion), 2017-2021
3. Global Scleroderma Therapeutics Market Forecast: Breakup by Drug Class (USD Billion), 2022-2027
4. Global Scleroderma Therapeutics Historical Market: Breakup by Indication (USD Billion), 2017-2021
5. Global Scleroderma Therapeutics Market Forecast: Breakup by Indication (USD Billion), 2022-2027
6. Global Scleroderma Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
7. Global Scleroderma Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
8. North America Scleroderma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
9. North America Scleroderma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
10. Europe Scleroderma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11. Europe Scleroderma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Asia Pacific Scleroderma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Asia Pacific Scleroderma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Latin America Scleroderma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Latin America Scleroderma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Middle East and Africa Scleroderma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Middle East and Africa Scleroderma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Global Scleroderma Therapeutics Market Structure
Key Questions Answered in the Report
In 2020, the global scleroderma therapeutics market attained a value of nearly USD 1.7 billion.
The market is projected to grow at a CAGR of 6.2% between 2021 and 2026.
The market is estimated to witness a healthy growth in the forecast period of 2022-2027 to reach USD 2.4 billion by 2026.
The major industry drivers include rising population, advancement of targeted biologics, and small molecular combination therapies and the use of off-label medications approved.
The key industry trends driving growth include the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others.
The leading indication types of the industry are systemic and localized.
The major players in the industry are F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, arGentis™ Pharmaceuticals, LLS, Kadmon Holdings, Inc., Emerald Health, Pharmaceuticals Inc., among others.
Analyst Review
The global scleroderma therapeutics market attained a value of USD 1.7 billion in 2020, driven by the advancement of targeted biologics, as well as small molecular combination therapies and the use of off-label medications approved. Aided by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment, the market is expected to witness a further growth in the forecast period of 2022-2027, growing at a CAGR of 6.2%. The market is projected to reach USD 2.4 billion by 2026.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others. The leading indication types of the industry are systemic and localized. The major regional markets for scleroderma therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, arGentis™ Pharmaceuticals, LLS, Kadmon Holdings, Inc., and Emerald Health Pharmaceuticals Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer...
The global hepatic disease treatment market attained a value of nearly USD 21.97 billion, driven by the rise in the prevalence of liver diseases. Aided by the increasing alcohol consumption and growin...
The global autism spectrum disorder therapeutics market attained a value of about USD 3.33 billion in 2021, driven by the rising research and development projects fostered by the government and market...
The global glaucoma therapeutics market attained a value of USD 7.24 billion in 2021, driven by the rising prevalence of glaucoma worldwide. Aided by the favourable reimbursement policies and growing ...
The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeli...
NEWSLETTER